Literature DB >> 939336

Pityriasis rubra pilaris. A clinico-pathological study with a special reference to autoradiography and histocompatibility antigens.

K M Niemi, M Kousa, K Storgards, J Karvonen.   

Abstract

In a clinical study, 27 of 31 cases of pityriasis rubra pilaris (PRP) had two or more of the following clinical features: erythroderma, well-confined healthy islands inside the inflammatory areas, keratoderma of the palms and soles, or visible follicular hyperkeratosis. Histological features were: perifollicular parakeratosis in 26 cases, hyperkeratosis in 27 cases; the number of granular layers varied greatly from case to case and within one specimen; acanthosis was eczematous in 20 cases and psoriasiform in 8 cases. Erythroderma in PRP in this study was self-healing, lasting 2-6 months with one exception, but PRP must as a whole be considered a mild, chronic disease lasting on average 5.7 years. Complete recovery occurred in only 8 patients and 5 of these had had an erythrodermic onset. Serum vitamin A level and tolerance test were normal. No immunological aberrations could be found. The HLA phenotype frequencies in PRP patients did not differ significantly from those in a Finnish control population. The autoradiographic study of the epidermal cells showed an increase in the cell production in the epidermis.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 939336

Source DB:  PubMed          Journal:  Dermatologica        ISSN: 0011-9075


  2 in total

1.  Pityriasis rubra pilaris epidermal cells in vitro. A comparison with normal and psoriatic cells.

Authors:  R A Harper; J Rispler
Journal:  Arch Dermatol Res       Date:  1977-12-27       Impact factor: 3.017

2.  Pityriasis rubra pilaris: a clinico-pathological and therapeutic study with special reference to histochemistry, autoradiography, and electron microscopy.

Authors:  O Braun-Falco; F Ryckmanns; C Schmoeckel; M Landthaler
Journal:  Arch Dermatol Res       Date:  1983       Impact factor: 3.017

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.